The capital is pricing semaglutide as an anti-aging drug. The SELECT trial (Novo Nordisk, n=17,604, primary endpoint MACE, published NEJM November 2023) delivered 20% relative risk reduction in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke -- in adults with pre-existing cardiovascular disease and obesity, no diabetes. The population studied had established disease. The population self-funding semaglutide at Singapore and Hong Kong concierge clinics does not.

The trial record is narrower than the thesis. No Phase 3 study of semaglutide or tirzepatide has enrolled metabolically healthy adults against an all-cause mortality or validated biological age primary endpoint. Both drugs have been tested exclusively in metabolically diseased populations (cardiovascular disease, type 2 diabetes, obesity comorbid with CVD). APAC family-office positions in Novo Nordisk and Eli Lilly, sized from 2023 onward on a narrative of population-level age extension, are priced above what the SELECT MACE result can support. The SELECT trial's median follow-up was 34.2 months; the capital thesis implies a mortality benefit that 34.2 months of MACE data in a CVD cohort cannot demonstrate. A metabolically healthy adult receiving semaglutide at a Singapore concierge clinic is outside the SELECT eligibility criteria and outside the weight management indication the Health Sciences Authority registers for adults with weight-related comorbidities under the Therapeutic Products Act.